Similar User
@EvanWeberPhD
@lab_rezvani
@MarsonLab
@MarcoRuella
@NathanSinghLab
@GruppSteve
@sitcancer
@parkerici
@KlebanoffLab
@jitcancer
@BLLPHD
@ArsenalBio
@ACIR_org
@DrFredLocke
@romeerizwan
Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at the @MGHCancerCenter with @MarcelaMaus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6011Wf0l @NEJM
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter! nej.md/3VnjUIq
High antigen density of BCMA: friend or foe to CAR T cells? jitc.bmj.com/content/10/9/e…
Not all people respond equally well to CAR-T cell therapy, a kind of immunotherapy that has dramatically improved blood cancer treatment. A new single-cell study by researchers at the Broad, @MassGeneralNews, and @DanaFarber could help reveal why. broad.io/carttherapy0912
A collaborative team at the @broadinstitute describes distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma. 🥼 @MarcelaMaus @gaddyg @Mark_Leick @Dr_KatieM @SatyenGohil Learn more: go.nature.com/3eQtbWc
.@MassGeneralNews researchers, led by ASGCT Board Member @MarcelaMaus & Associate Member @Mark_Leick, developed a novel treatment strategy that has the potential to bring the benefits of #CART #celltherapy to patients with acute myeloid #leukemia (#AML). bit.ly/3kq9JPP
Exciting new CAR design for AML from our lab! Now online @Cancer_Cell @MGHCancerCenter @MGBInnovation
Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC @Cancer_Cell cell.com/cancer-cell/fu…
Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC @Cancer_Cell cell.com/cancer-cell/fu…
Saw @Marcelamaus present this at #AACR2022 - really beautiful story! congrats.
Online at @nature: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by @MarcelaMaus and colleagues nature.com/articles/s4158…
How do CAR-T cells kill tumor cells? - It depends… Exciting work @Nature by @MarcelaMaus Rebecca Larson & colleagues on the role of IFNg signaling in CAR-T mediated killing. Congrats to the entire team! nature.com/articles/s4158…
✨ New today in @Nature! Dr. @MarcelaMaus at @harvardmed and colleagues demonstrated that liquid 💧 and solid 🧊 tumors differ in their interactions with #CAR T cells, particularly in regards to the IFNγR pathway. go.nature.com/3xr4bfz
Critical findings from a study @Nature led by @MarcelaMaus differentiating CAR T-cell efficacy against liquid versus solid tumors like #Glioblastoma ...INFg is the key! nature.com/articles/s4158…
Online at @nature: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by @MarcelaMaus and colleagues nature.com/articles/s4158…
Today #AACR22, don’t miss @njharlen presenting on single-cell analysis of cellular dynamics underlying clinical response to #CARTcell therapy in #collab work with Cathy Wu and @MarcelaMaus labs (Talk #3575). Then, read more of the story @medrxiv: medrxiv.org/content/10.110…
Mechanisms of CAR T-cell therapy + #immunotherapy being discussed today at #AACR22 by @StBaldricks @SU2C #PediatricCancer Dream Team Co-leader Dr. Crystal Mackall + Innovative Rsch Grant Recipient @MarcelaMaus @MackallLab @StanfordCancer @MassGeneralNews abstractsonline.com/pp8/#!/10517/s…
Excited to share the latest work from my PhD! We performed the first CRISPR activation screen to identify genes that drive solid tumor resistance to T cell-mediated cytotoxicity. A thread 1/X nature.com/articles/s4146…
Decades of studying the immune system's response to a virus help #researchers discover new treatments and potential cures to deadly diseases. Learn how this team at Mass General Brigham is working to change medicine. nyti.ms/3JX7iie
Our 4th most downloaded article of 2021: Recent advances and discoveries in the mechanisms and functions of CAR T cells by RC Larson & @MarcelaMaus go.nature.com/2Y8lcbL @harvardmed #NRCtop10of2021 #Immunotherapy
New #JITC short report: Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) bit.ly/3JOiwqc @MJFzeta @MarcelaMaus
United States Trends
- 1. Dodgers 45,9 B posts
- 2. Lakers 37 B posts
- 3. #DWTS 71,5 B posts
- 4. Chandler 38,3 B posts
- 5. Duke 38,1 B posts
- 6. Ilona 12,4 B posts
- 7. Joey 26,9 B posts
- 8. #kaicenat 3.651 posts
- 9. Dylan Harper N/A
- 10. Sasaki 8.915 posts
- 11. Cooper Flagg 4.923 posts
- 12. Soto 25,8 B posts
- 13. Ohtani 6.520 posts
- 14. Beal 6.844 posts
- 15. Matt Allocco N/A
- 16. Glasnow 2.697 posts
- 17. Suns 17,9 B posts
- 18. Stephen 50,9 B posts
- 19. Kansas 19,8 B posts
- 20. Jenna 9.315 posts
Who to follow
-
Evan Weber
@EvanWeberPhD -
Katy Rezvani, M.D., Ph.D
@lab_rezvani -
Marson Lab
@MarsonLab -
Marco Ruella
@MarcoRuella -
Nathan Singh
@NathanSinghLab -
Stephan Grupp MD PhD
@GruppSteve -
Society for Immunotherapy of Cancer
@sitcancer -
Parker Institute for Cancer Immunotherapy
@parkerici -
Klebanoff_Lab
@KlebanoffLab -
Journal for ImmunoTherapy of Cancer
@jitcancer -
Bruce Levine, Ph.D. 🇺🇦
@BLLPHD -
ArsenalBio
@ArsenalBio -
ACIR
@ACIR_org -
Frederick L. Locke
@DrFredLocke -
Rizwan Romee
@romeerizwan
Something went wrong.
Something went wrong.